Paper Details

  1. Home
  2. Paper Details

Chiral discrimination of cyclodecapeptide to anti-COVID-19 clinical candidates: a theoretical study.

Author: JiShuangshuang, WangXinqing, YangJian, ZhuYanyan

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.

Overview

This study investigated the chiral recognition of four clinical candidate molecules (bucillamine, molnupiravir, azvudine, and VV116) and their isomers using cyclic decapeptide as a host molecule and theoretical computational methods. The study found that cyclic decapeptide can distinguish between bucillamine, molnupiravir, and their respective isomers, and some isomers of azvudine and VV116.
Paper Details　
Original Abstract of the Article :
Various undesirable side effects are frequently associated with isomers of chiral clinical agents. The separation of chiral medicines remains a challenging issue in the medicines research. In this work, we employed cyclic decapeptide as the host molecule and the M06-2X theoretical computational meth...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10011793/

データ提供：米国国立医学図書館（NLM）

Chiral Discrimination of Cyclodecapeptide for Anti-COVID-19 Clinical Candidates

The pharmaceutical world is constantly seeking ways to improve drug efficacy and safety. This research explores the potential of using cyclodecapeptide, a cyclic peptide, for chiral discrimination of clinical candidates relevant for the treatment of COVID-19. Using theoretical computational methods, the researchers investigated the ability of cyclodecapeptide to distinguish between different isomers of drugs like bucillamine, molnupiravir, azvudine, and VV116. The study found that cyclodecapeptide could potentially separate certain isomers of these drugs, suggesting its potential use in purifying and enhancing the effectiveness of these medications.

The Potential of Cyclodecapeptide in Drug Development

The study's findings suggest that cyclodecapeptide could play a crucial role in the development of more effective and safer anti-COVID-19 treatments. By separating different isomers, it could help ensure that only the desired active component of a drug is administered to patients, potentially leading to fewer side effects and improved therapeutic outcomes.

The Health Implications and Practical Applications

The use of chiral discrimination in drug development could lead to more targeted and effective treatments for COVID-19, minimizing unwanted side effects and improving patient outcomes. This research has the potential to significantly impact the fight against COVID-19 and future pharmaceutical development.

Dr.Camel's Conclusion

This research is like a desert mirage, promising a future where medications are more specific and effective. Cyclodecapeptide's potential for chiral discrimination could revolutionize drug development, leading to safer and more targeted therapies for COVID-19 and beyond.

Date :
  1. Date Completed n.d.
  2. Date Revised 2023-09-28
Further Info :

Pubmed ID

37363041

DOI: Digital Object Identifier

PMC10011793

Related Literature

Article Analysis
・Side Effects of molnupiravir
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.